Chronic Lymphocytic Leukemia

Oncology·MeSH: Leukemia, Lymphocytic, Chronic, B-Cell

Prevalence

20.0 / 100K

Incidence

4.7 / 100K/yr

99 drugs in development·38 companies·76 clinical trials

Drug Pipeline by Phase

Phase 3(36)
DrugCompany
AcalabrutinibAbbVie Inc. (ABBV)
AcalabrutinibMerus N.V. (MRUS)
AcalabrutinibMerck & Co., Inc. (MRK)
alxn2075ALEXION PHARMACEUTICALS, INC. (ALXN)
bendamustineLOXO ONCOLOGY, INC. (LOXO)
bendamustineBeOne Medicines Ltd. (ONC)
bendamustineBeOne Medicines Ltd. (ONC)
BendamustineENANTA PHARMACEUTICALS INC (ENTA)
BendamustineBeOne Medicines Ltd. (ONC)
bgb-16673BeOne Medicines Ltd. (ONC)
BGB-16673ENANTA PHARMACEUTICALS INC (ENTA)
BGB-16673BeOne Medicines Ltd. (ONC)
BGB-16673Merus N.V. (MRUS)
gamunex-cGrifols S.A. (GRFS)
IbrutinibAbbVie Inc. (ABBV)
IbrutinibMerck & Co., Inc. (MRK)
IdelalisibMerus N.V. (MRUS)
IdelalisibENANTA PHARMACEUTICALS INC (ENTA)
liso-celCELGENE CORP /DE/ (CELG)
NemtabrutinibMerus N.V. (MRUS)
obinutuzumabBeOne Medicines Ltd. (ONC)
ObinutuzumabASTRAZENECA PLC (AZN)
ObinutuzumabAbbVie Inc. (ABBV)
parsaclisibIncyte Corp. (INCY)
PirtobrutinibBeOne Medicines Ltd. (ONC)
RoginolisibENANTA PHARMACEUTICALS INC (ENTA)
sonrotoclaxBeOne Medicines Ltd. (ONC)
SonrotoclaxENANTA PHARMACEUTICALS INC (ENTA)
SonrotoclaxFilana Therapeutics Inc. (FLNA)
SonrotoclaxBeOne Medicines Ltd. (ONC)
tafasitamabIncyte Corp. (INCY)
UblituximabASTRAZENECA PLC (AZN)
VenetoclaxBeOne Medicines Ltd. (ONC)
VenetoclaxASTRAZENECA PLC (AZN)
ZanubrutinibFilana Therapeutics Inc. (FLNA)
zilovertamabOncternal Therapeutics, Inc. (ONCT)
Phase 1(25)
DrugCompany
ABT-263AbbVie Inc. (ABBV)
apg-2575ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
apg2575ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
bendamustineAbbVie Inc. (ABBV)
BP1002BIO-PATH HOLDINGS, INC. (BPTH)
duvelisibAbbVie Inc. (ABBV)
epcoritamabGenmab A/S (GMAB)
EpcoritamabFilana Therapeutics Inc. (FLNA)
EpcoritamabELI LILLY & Co (LLY)
EpcoritamabENANTA PHARMACEUTICALS INC (ENTA)
FCRAbbVie Inc. (ABBV)
FludarabinePRECIGEN, INC. (PGEN)
High dose IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOV-2001IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IPI-145Filana Therapeutics Inc. (FLNA)
JCAR017 + ibrutinibMerus N.V. (MRUS)
kur-502Athenex, Inc. (ATNX)
Low dose IL-2IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
mb-106MUSTANG BIO, INC. (MBIO)
NX-2127Nurix Therapeutics, Inc. (NRIX)
NX-5948Keros Therapeutics, Inc. (KROS)
NX-5948Nurix Therapeutics, Inc. (NRIX)
OlaparibRepare Therapeutics Inc. (RPTX)
PRGN-3007PRECIGEN, INC. (PGEN)

Compare drugs

belrapzo vs clonoSEQbelrapzo vs Jaypircabelrapzo vs venetoclax

Frequently asked questions

How many drugs are in development for Chronic Lymphocytic Leukemia?

BioSniper tracks 99 drugs in development for Chronic Lymphocytic Leukemia across 38 companies.

How many clinical trials target Chronic Lymphocytic Leukemia?

There are 76 clinical trials targeting Chronic Lymphocytic Leukemia tracked by BioSniper.

What is the prevalence of Chronic Lymphocytic Leukemia?

The estimated prevalence of Chronic Lymphocytic Leukemia is approximately 20.0 per 100,000 population.

Deep-dive into Chronic Lymphocytic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis